Establishing the First Mobile Stroke Unit in the United States

被引:104
作者
Parker, Stephanie A. [1 ]
Bowry, Ritvij [1 ]
Wu, Tzu-Ching [1 ]
Noser, Elizabeth A. [1 ]
Jackson, Kamilah [1 ]
Richardson, Laura [2 ]
Persse, David [1 ,3 ]
Grotta, James C. [4 ]
机构
[1] Univ Texas Houston, Sch Med, Dept Neurol, Houston, TX USA
[2] Frazer Ltd, Houston, TX USA
[3] City Houston Emergency Med Serv, Dept Emergency Med, Houston, TX USA
[4] Mem Hermann Hosp, Clin Innovat & Res Inst, Houston, TX USA
关键词
acute stroke; ambulance; EMS; prehospital; thrombolysis; ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; RT-PA STROKE; POOLED ANALYSIS; TIME; TRIAL; NINDS; THROMBOLYSIS; ASSOCIATION; MANAGEMENT;
D O I
10.1161/STROKEAHA.114.007993
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Recently, the Mobile Stroke Unit (MSU) concept was introduced in Germany demonstrating prehospital treatment of more patients within the first hour of symptom onset. However, the details and complexities of establishing such a program in the United States are unknown. We describe the steps involved in setting up the first MSU in the United States. Methods-Implementation included establishing leadership, fund-raising, purchase and build-out, knitting a collaborative consortium of community stakeholders, writing protocols to ensure accountability, radiation safety, purchasing supplies, licensing, insurance, establishing a base station, developing a communication plan with city Emergency Medical Services, Emergency Medical Service training, staffing, and designing a research protocol. Results-The MSU was introduced after approximate to 1 year of preparation. Major obstacles to establishing the MSU were primarily obtaining funding, licensure, documenting radiation safety protocols, and establishing a smooth communication system with Emergency Medical Services. During an 8 week run-in phase, approximate to 2 patients were treated with recombinant tissue-type plasminogen activator per week, one-third within 60 minutes of symptom onset, with no complications. A randomized study to determine clinical outcomes, telemedicine reliability and accuracy, and cost effectiveness was formulated and has begun. Conclusion-The first MSU in the United States has been introduced in Houston, TX. The steps needed to accomplish this are described.
引用
收藏
页码:1384 / 1391
页数:8
相关论文
共 14 条
[1]   Effects of Golden Hour Thrombolysis A Prehospital Acute Neurological Treatment and Optimization of Medical Care in Stroke (PHANTOM-S) Substudy [J].
Ebinger, Martin ;
Kunz, Alexander ;
Wendt, Matthias ;
Rozanski, Michal ;
Winter, Benjamin ;
Waldschmidt, Carolin ;
Weber, Joachim ;
Villringer, Kersten ;
Fiebach, Jochen B. ;
Audebert, Heinrich J. .
JAMA NEUROLOGY, 2015, 72 (01) :25-30
[2]   Effect of the Use of Ambulance-Based Thrombolysis on Time to Thrombolysis in Acute Ischemic Stroke A Randomized Clinical Trial [J].
Ebinger, Martin ;
Winter, Benjamin ;
Wendt, Matthias ;
Weber, Joachim E. ;
Waldschmidt, Carolin ;
Rozanski, Michal ;
Kunz, Alexander ;
Koch, Peter ;
Kellner, Philipp A. ;
Gierhake, Daniel ;
Villringer, Kersten ;
Fiebach, Jochen B. ;
Grittner, Ulrike ;
Hartmann, Andreas ;
Mackert, Bruno-Marcel ;
Endres, Matthias ;
Audebert, Heinrich J. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (16) :1622-1631
[3]   Door-to-Needle Times for Tissue Plasminogen Activator Administration and Clinical Outcomes in Acute Ischemic Stroke Before and After a Quality Improvement Initiative [J].
Fonarow, Gregg C. ;
Zhao, Xin ;
Smith, Eric E. ;
Saver, Jeffrey L. ;
Reeves, Mathew J. ;
Bhatt, Deepak L. ;
Xian, Ying ;
Hernandez, Adrian F. ;
Peterson, Eric D. ;
Schwamm, Lee H. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (16) :1632-1640
[4]   Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke Patient Characteristics, Hospital Factors, and Outcomes Associated With Door-to-Needle Times Within 60 Minutes [J].
Fonarow, Gregg C. ;
Smith, Eric E. ;
Saver, Jeffrey L. ;
Reeves, Mathew J. ;
Bhatt, Deepak L. ;
Grau-Sepulveda, Maria V. ;
Olson, DaiWai M. ;
Hernandez, Adrian F. ;
Peterson, Eric D. ;
Schwamm, Lee H. .
CIRCULATION, 2011, 123 (07) :750-U184
[5]  
Hacke W, 2004, LANCET, V363, P768
[6]   Guidelines for the Early Management of Patients With Acute Ischemic Stroke A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association [J].
Jauch, Edward C. ;
Saver, Jeffrey L. ;
Adams, Harold P., Jr. ;
Bruno, Askiel ;
Connors, J. J. ;
Demaerschalk, Bart M. ;
Khatri, Pooja ;
McMullan, Paul W., Jr. ;
Qureshi, Adnan I. ;
Rosenfield, Kenneth ;
Scott, Phillip A. ;
Summers, Debbie R. ;
Wang, David Z. ;
Wintermark, Max ;
Yonas, Howard .
STROKE, 2013, 44 (03) :870-947
[7]   Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial [J].
Khatri, Pooja ;
Yeatts, Sharon D. ;
Mazighi, Mikael ;
Broderick, Joseph P. ;
Liebeskind, David S. ;
Demchuk, Andrew M. ;
Amarenco, Pierre ;
Carrozzella, Janice ;
Spilker, Judith ;
Foster, Lydia D. ;
Goyal, Mayank ;
Hill, Michael D. ;
Palesch, Yuko Y. ;
Jauch, Edward C. ;
Haley, E. Clarke ;
Vagal, Achala ;
Tomsick, Thomas A. .
LANCET NEUROLOGY, 2014, 13 (06) :567-574
[8]   Treatment Time-Specific Number Needed to Treat Estimates for Tissue Plasminogen Activator Therapy in Acute Stroke Based on Shifts Over the Entire Range of the Modified Rankin Scale [J].
Lansberg, Maarten G. ;
Schrooten, Maarten ;
Bluhmki, Erich ;
Thijs, Vincent N. ;
Saver, Jeffrey L. .
STROKE, 2009, 40 (06) :2079-2084
[9]   Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials [J].
Lees, Kennedy R. ;
Bluhmki, Erich ;
von Kummer, Ruediger ;
Brott, Thomas G. ;
Toni, Danilo ;
Grotta, James C. ;
Albers, Gregory W. ;
Kaste, Markku ;
Marler, John R. ;
Hamilton, Scott A. ;
Tilley, Barbara C. ;
Davis, Stephen M. ;
Donnan, Geoffrey A. ;
Hacke, Werner ;
Ninds, Ecass Atlantis .
LANCET, 2010, 375 (9727) :1695-1703
[10]   TISSUE-PLASMINOGEN ACTIVATOR FOR ACUTE ISCHEMIC STROKE [J].
MARLER, JR ;
BROTT, T ;
BRODERICK, J ;
KOTHARI, R ;
ODONOGHUE, M ;
BARSAN, W ;
TOMSICK, T ;
SPILKER, J ;
MILLER, R ;
SAUERBECK, L ;
JARRELL, J ;
KELLY, J ;
PERKINS, T ;
MCDONALD, T ;
RORICK, M ;
HICKEY, C ;
ARMITAGE, J ;
PERRY, C ;
THALINGER, K ;
RHUDE, R ;
SCHILL, J ;
BECKER, PS ;
HEATH, RS ;
ADAMS, D ;
REED, R ;
KLEI, M ;
HUGHES, S ;
ANTHONY, J ;
BAUDENDISTEL, D ;
ZADICOFF, C ;
RYMER, M ;
BETTINGER, I ;
LAUBINGER, P ;
SCHMERLER, M ;
MEIROSE, G ;
LYDEN, P ;
RAPP, K ;
BABCOCK, T ;
DAUM, P ;
PERSONA, D ;
BRODY, M ;
JACKSON, C ;
LEWIS, S ;
LISS, J ;
MAHDAVI, Z ;
ROTHROCK, J ;
TOM, T ;
ZWEIFLER, R ;
DUNFORD, J ;
ZIVIN, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (24) :1581-1587